Management of Acute Left-Sided Chest Pain in a Patient with Ongoing Pulmonary Embolism

Immediate Assessment and Risk Stratification

The European Society of Cardiology recommends continuing apixaban 5mg twice daily and immediately assessing hemodynamic stability to determine if rescue thrombolysis is needed in patients with chest pain on therapeutic anticoagulation for pulmonary embolism 1
The European Society of Cardiology suggests checking vital signs immediately, with systolic blood pressure <90 mmHg defining high-risk pulmonary embolism requiring thrombolysis 2, 3
Bedside echocardiography should be performed to assess right ventricular function and differentiate pulmonary embolism progression from other acute cardiac conditions, such as myocardial infarction, pericarditis, or aortic dissection 2, 3
Assessment for signs of shock, including engorged neck veins, right ventricular gallop, and unexplained hypoxia, is crucial, as these suggest massive pulmonary embolism 4

The European Society of Cardiology recommends administering rescue thrombolytic therapy immediately in patients with hemodynamic deterioration despite anticoagulation, with a Class I recommendation 5, 1
Alteplase 50mg IV bolus or 100mg over 90 minutes can be given in deteriorating patients 4
Contraindications to thrombolysis should be ignored in life-threatening pulmonary embolism 4
If thrombolysis fails or is contraindicated, surgical embolectomy or catheter-directed treatment should be considered 3, 6
The European Society of Cardiology recommends continuing apixaban at the current therapeutic dose and investigating alternative causes of chest pain in hemodynamically stable patients 5, 1
Routine administration of thrombolysis is not recommended in intermediate- or low-risk pulmonary embolism, with a Class III recommendation 5, 1

Verifying apixaban dosing is appropriate, with a standard dose of 10mg twice daily for 7 days, then 5mg twice daily, is essential 5
Assessing for treatment failure indicators, including recurrent symptoms on therapeutic anticoagulation, and considering alternative diagnoses, such as acute coronary syndrome, pericarditis, or musculoskeletal pain, is crucial 2
Evaluating medication adherence, as missed doses can lead to inadequate anticoagulation, is important 3

Switching from apixaban to heparin is not recommended unless planning thrombolysis or the patient has severe renal impairment (CrCl <30 mL/min) 5, 1
Routinely inserting IVC filters is not recommended in pulmonary embolism management 5, 1
Delaying thrombolysis in hemodynamically unstable patients can result in a mortality benefit that is time-dependent 4
Assuming chest pain equals pulmonary embolism progression without considering cardiac ischemia as a competing diagnosis requiring different management is a common pitfall 2

Reassessing clinical status frequently over the next 24-48 hours and having a contingency plan ready for clinical deterioration is essential 3
Ensuring therapeutic anticoagulation continues for a minimum of 3 months total is crucial 5, 1
Scheduling routine reevaluation at 3-6 months post-pulmonary embolism to assess for chronic complications is recommended 3, 1, 7